3 FORBES ROAD, LEXINGTON, MA
Other Events
Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
Closes Transaction with Zydus Pharmaceuticals
Dr. Garo Armen Appointed Interim CFO of Agenus Inc.
Material disclosure
Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
FY 2025
Q3
Q2
Q1
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13D - Ownership Report
Definitive Revised Proxy Statement
Correspondence
Submission Upload
Automatic Shelf Registration Statement